Welcome to our dedicated page for IOVANCE BIOTHERAPEUTICS SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IOVANCE BIOTHERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IOVANCE BIOTHERAPEUTICS's regulatory disclosures and financial reporting.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of common stock of IOVANCE BIOTHERAPEUTICS INC as of 12/31/2025. State Street reports beneficial ownership of 20,161,445 shares, representing 5.1% of the company’s common stock.
State Street reports no sole voting or dispositive power, with 19,204,365 shares subject to shared voting power and 20,161,445 shares subject to shared dispositive power. Subsidiaries involved include SSGA Funds Management and various State Street Global Advisors entities. State Street certifies the holdings are in the ordinary course of business and not for changing or influencing control of Iovance.
Iovance Biotherapeutics, Inc. filed a report describing an updated corporate presentation it will use with healthcare conference audiences, analysts, current stockholders, and others. In that presentation, the company states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of sales for its therapy Amtagvi. The updated slide deck is provided as Exhibit 99.1 to the report.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported a routine insider equity transaction involving its Chief Regulatory Officer. On 12/01/2025, restricted stock units (RSUs) covering 5,469 shares of common stock vested, and these shares were acquired at an exercise price of $0 as part of the equity award terms.
To cover mandatory tax withholding triggered by the RSU vesting, the company withheld 2,467 shares at a price of $2.23 per share, which was not an open market sale. After this withholding, the officer beneficially owned 215,859 shares of common stock directly. The filing also notes that 27,348 RSUs from the March 1, 2024 grant remain outstanding, scheduled to vest in equal quarterly installments, each RSU representing one share of common stock.
Iovance Biotherapeutics (IOVA) filed a Form S-8 to register an additional 1,000,000 shares of common stock for its 2020 Employee Stock Purchase Plan, which was amended on June 10, 2025. The shares are the same class as those previously registered for this plan.
The filing incorporates by reference earlier S-8 registrations related to the ESPP and includes customary exhibits, including the legal opinion and auditor consent.
Iovance Biotherapeutics filed its Q3 2025 10‑Q, reporting total revenue of $67.455 million and a net loss of $91.253 million. Year to date, revenue reached $176.731 million as Amtagvi and Proleukin sales scaled.
Operating costs remained heavy: cost of sales $38.477 million, R&D $75.174 million, SG&A $34.555 million, plus $5.143 million in restructuring charges, driving a loss from operations of $94.901 million. Cash used in operations for the first nine months was $249.843 million.
Liquidity was supported by $306.8 million in cash, cash equivalents, short‑term investments, and restricted cash as of September 30, 2025, and the company states it has sufficient capital to fund planned operations for at least the next twelve months. Shares outstanding were 396,967,970 as of October 15, 2025.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics (IOVA), reported transactions dated 09/02/2025 on a Form 4. The filing shows 52,086 shares of common stock acquired upon RSU vesting at no cash price and 22,127 shares withheld by the issuer to satisfy mandatory tax withholding at a reported withholding price of $2.19 per share. After these transactions the filing reports 456,690 shares beneficially owned following the vesting event and 434,563 shares remaining after the tax-withholding deduction. The filing also details newly vested restricted stock units (RSUs): 10,417 and 41,669, with resulting beneficial ownership figures shown in the form.
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reported transactions on 09/02/2025 related to restricted stock units (RSUs). On that date 5,470 RSUs vested and were converted into shares, and the issuer withheld 2,467 shares to satisfy mandatory tax withholding. After these transactions the reporting person beneficially owned 212,857 shares (the filing shows 215,324 before withholding). The filing also discloses that 32,817 RSUs remain outstanding from the March 1, 2024 grant and remaining RSUs will vest in equal quarterly installments.
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported changes in beneficial ownership on 09/02/2025. On that date 12,697 shares of common stock were acquired upon vesting of restricted stock units (RSUs). To satisfy mandatory tax withholding, the issuer withheld 6,448 shares at an indicated per-share tax withholding price of $2.19, leaving 105,409 shares reported as beneficially owned after the withholding.
Table II shows RSU activity: 3,907 and 8,790 RSUs were reported as vested under two grants, representing underlying common stock amounts reflected in the filing. The reporting person signed the Form 4 on 09/04/2025.
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), reported equity changes on 09/02/2025. Restricted stock units (RSUs) vested that day, resulting in the acquisition of 12,306 common shares (recorded as Code M) at no cash price. To satisfy mandatory tax withholding on the vesting, the issuer withheld 6,250 shares (recorded as Code F) at a price of $2.19 per share rather than an open-market sale, leaving 99,689 shares beneficially owned after the transactions. The filing also lists vested RSU components of 3,516 and 8,790 underlying common shares, with remaining RSU schedules described in the explanatory notes.